BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int. 2011;31:840-849. [PMID: 21645215 DOI: 10.1111/j.1478-3231.2011.02504.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Hendrikx T, Porsch F, Kiss MG, Rajcic D, Papac-Miličević N, Hoebinger C, Göderle L, Hladik A, Shaw LE, Horstmann H, Knapp S, Derdak S, Bilban M, Heintz L, Krawczyk M, Paternostro R, Trauner M, Farlik M, Wolf D, Binder CJ. Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. J Hepatol 2022:S0168-8278(22)00359-2. [PMID: 35750138 DOI: 10.1016/j.jhep.2022.06.004] [Reference Citation Analysis]
2 Wang W, Liu X, Wei P, Ye F, Chen Y, Shi L, Zhang X, Li J, Lin S, Yang X. SPP1 and CXCL9 Promote Non-alcoholic Steatohepatitis Progression Based on Bioinformatics Analysis and Experimental Studies. Front Med 2022;9:862278. [DOI: 10.3389/fmed.2022.862278] [Reference Citation Analysis]
3 Mirshahi F, Aqbi HF, Isbell M, Manjili SH, Guo C, Saneshaw M, Dozmorov M, Khosla A, Wack K, Carrasco-Zevallos OM, Idowu MO, Wang XY, Sanyal AJ, Manjili MH, Bandyopadhyay D. Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. Cell Rep 2022;38:110454. [PMID: 35235789 DOI: 10.1016/j.celrep.2022.110454] [Reference Citation Analysis]
4 Liu G, Wang X, Yang T, Yan Y, Xiang T, Yang L, Luo X. High Interleukin-8 Levels Associated With Decreased Survival in Patients With Cirrhosis Following Transjugular Intrahepatic Portosystemic Shunt. Front Med 2022;9:829245. [DOI: 10.3389/fmed.2022.829245] [Reference Citation Analysis]
5 Li Y, Dong J, Zhou Y, Ye X, Cai Z, Zhang X, Shen L, Zhang M, Zhang W, Cai J. Therapeutic effects of CXCL9-overexpressing human umbilical cord mesenchymal stem cells on liver fibrosis in rats. Biochem Biophys Res Commun 2021;584:87-94. [PMID: 34775285 DOI: 10.1016/j.bbrc.2021.10.078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
7 Leavitt C, Zakai NA, Auer P, Cushman M, Lange EM, Levitan EB, Olson N, Thornton TA, Tracy RP, Wilson JG, Lange LA, Reiner AP, Raffield LM. Interferon gamma-induced protein 10 (IP-10) and cardiovascular disease in African Americans. PLoS One 2020;15:e0231013. [PMID: 32240245 DOI: 10.1371/journal.pone.0231013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Klindt C, Reich M, Hellwig B, Stindt J, Rahnenführer J, Hengstler JG, Köhrer K, Schoonjans K, Häussinger D, Keitel V. The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver. Cells 2019;8:E1467. [PMID: 31752395 DOI: 10.3390/cells8111467] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
9 Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol 2019;166:212-21. [PMID: 31129048 DOI: 10.1016/j.bcp.2019.05.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
10 Chalin A, Lefevre B, Devisme C, Barget N, Amiot L, Samson M. Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection. Cytokine 2019;117:72-8. [PMID: 30826602 DOI: 10.1016/j.cyto.2019.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Chen W, Zhang J, Fan HN, Zhu JS. Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2018;11:1756284818815184. [PMID: 30574191 DOI: 10.1177/1756284818815184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
12 Lee H, Ghill B, Park E, Park C, Choi W, Lee J. Changes in the Ratio of T Helper 1 to T Helper 2 Signature Cytokines in Patients Undergoing Living Donor Liver Transplantation Surgery: A Prospective Controlled Study. Transplantation Proceedings 2018;50:3621-5. [DOI: 10.1016/j.transproceed.2018.08.055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, Butt T, Rasmiena AA, Kaur S, Gulati T, Goh PK, Treloar AE, Archer S, Brown WA, Muller M, Watt MJ, Ohara O, McLean CA, Tiganis T. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175:1289-1306.e20. [PMID: 30454647 DOI: 10.1016/j.cell.2018.09.053] [Cited by in Crossref: 98] [Cited by in F6Publishing: 135] [Article Influence: 24.5] [Reference Citation Analysis]
14 Riva A, Patel V, Kurioka A, Jeffery HC, Wright G, Tarff S, Shawcross D, Ryan JM, Evans A, Azarian S, Bajaj JS, Fagan A, Patel V, Mehta K, Lopez C, Simonova M, Katzarov K, Hadzhiolova T, Pavlova S, Wendon JA, Oo YH, Klenerman P, Williams R, Chokshi S. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut 2018;67:918-30. [PMID: 29097439 DOI: 10.1136/gutjnl-2017-314458] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]
15 de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P. NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatol Commun 2018;2:492-503. [PMID: 29761166 DOI: 10.1002/hep4.1170] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
16 Lehmann JM, Claus K, Jansen C, Pohlmann A, Schierwagen R, Meyer C, Thomas D, Manekeller S, Claria J, Strassburg CP, Trautwein C, Wasmuth HE, Berres ML, Trebicka J. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int 2018;38:875-84. [PMID: 29105936 DOI: 10.1111/liv.13610] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
17 Wang XL, Chen XJ, Ye HH, Xing LX, Han XY, Cheng ZJ, Huang SJ. Association of mRNA expression level of IP-10 in peripheral blood mononuclear cells with HBV-associated acute-on-chronic liver failure and its prognosis. J Huazhong Univ Sci Technolog Med Sci 2017;37:755-60. [PMID: 29058291 DOI: 10.1007/s11596-017-1800-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Jiménez-Sousa MÁ, Gómez-Moreno AZ, Pineda-Tenor D, Medrano LM, Sánchez-Ruano JJ, Fernández-Rodríguez A, Artaza-Varasa T, Saura-Montalban J, Vázquez-Morón S, Ryan P, Resino S. CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study. Clin Transl Med 2017;6:26. [PMID: 28755163 DOI: 10.1186/s40169-017-0156-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
19 Stephanie M, Susufi YG, Krisnuhoni E, Gani RA, Yunihastuti E, Lee S, Tanaskovic S, Price P. Short Communication: Few Liver-Infiltrating Cells Express CXCR3 in HIV/HCV Patients Commencing Antiretroviral Therapy. AIDS Res Hum Retroviruses 2016;32:1202-4. [PMID: 27250905 DOI: 10.1089/AID.2016.0042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Carbone M, Invernizzi P. Novel treatments targeting immune-related mechanisms in primary biliary cholangitis. Clin Liver Dis (Hoboken) 2016;8:127-31. [PMID: 31041080 DOI: 10.1002/cld.587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Gadd VL, Patel PJ, Jose S, Horsfall L, Powell EE, Irvine KM. Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation. PLoS One 2016;11:e0157771. [PMID: 27309850 DOI: 10.1371/journal.pone.0157771] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
22 Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, Goodfellow VS, Malhi H, Gores GJ. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology 2016;63:731-44. [PMID: 26406121 DOI: 10.1002/hep.28252] [Cited by in Crossref: 126] [Cited by in F6Publishing: 133] [Article Influence: 21.0] [Reference Citation Analysis]
23 Berres ML, Lehmann J, Jansen C, Görtzen J, Meyer C, Thomas D, Zimmermann HW, Kroy D, Schumacher F, Strassburg CP, Sauerbruch T, Trautwein C, Wasmuth HE, Trebicka J. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver Int 2016;36:386-94. [PMID: 26212075 DOI: 10.1111/liv.12922] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
24 Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S. CXCR3 ligands in disease and therapy. Cytokine & Growth Factor Reviews 2015;26:311-27. [DOI: 10.1016/j.cytogfr.2014.11.009] [Cited by in Crossref: 156] [Cited by in F6Publishing: 167] [Article Influence: 22.3] [Reference Citation Analysis]
25 Solinas A, Calvisi DF. Lessons from rare tumors: Hepatic lymphoepithelioma-like carcinomas. World J Gastroenterol 2015; 21(12): 3472-3479 [PMID: 25834311 DOI: 10.3748/wjg.v21.i12.3472] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
26 Bataller R, Mandrekar P. Identifying molecular targets to improve immune function in alcoholic hepatitis. Gastroenterology 2015;148:498-501. [PMID: 25613314 DOI: 10.1053/j.gastro.2015.01.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
27 Berres ML, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Hepatol. 2015;62:332-339. [PMID: 25457205 DOI: 10.1016/j.jhep.2014.09.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
28 Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594. e1. [PMID: 25066692 DOI: 10.1053/j.gastro.2014.06.043] [Cited by in Crossref: 406] [Cited by in F6Publishing: 457] [Article Influence: 50.8] [Reference Citation Analysis]
29 Iredale JP, Bataller R. Identifying molecular factors that contribute to resolution of liver fibrosis. Gastroenterology. 2014;146:1160-1164. [PMID: 24680971 DOI: 10.1053/j.gastro.2014.03.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
30 Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics 2014;46:223-44. [PMID: 24520152 DOI: 10.1152/physiolgenomics.00158.2013] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 15.5] [Reference Citation Analysis]
31 Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27:273-280. [PMID: 23712302 DOI: 10.1155/2013/512624] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 11.3] [Reference Citation Analysis]
32 Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B: IL-22, HBcrAg, and ETV therapy in CH-B. Hepatol Res 2014;44:E172-80. [DOI: 10.1111/hepr.12287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
33 de Niet A, de Bruijne J, Plat-sinnige MT, Takkenberg R, van Lier R, Reesink H, van Leeuwen E. Upregulation of CXCR3 expression on CD8+ T cells due to the pervasive influence of chronic hepatitis B and C virus infection. Human Immunology 2013;74:899-906. [DOI: 10.1016/j.humimm.2013.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
34 Chen L, Lv J, Wen X, Niu J. CXC chemokine IP-10: a key actor in liver disease? Hepatol Int 2013;7:798-804. [DOI: 10.1007/s12072-013-9445-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
35 Shen J, Gao J, Chen C, Lu H, Hu G, Shen J, Zhu S, Wu M, Wang X, Qian L. Antifibrotic role of chemokine CXCL9 in experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. Cytokine. 2013;64:382-394. [PMID: 23819906 DOI: 10.1016/j.cyto.2013.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
36 Karim S, Liaskou E, Hadley S, Youster J, Faint J, Adams DH, Lalor PF. An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013;132:131-141. [PMID: 23300006 DOI: 10.1093/toxsci/kfs337] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
37 Eisenhardt M, Glässner A, Krämer B, Körner C, Sibbing B, Kokordelis P, Nischalke HD, Sauerbruch T, Spengler U, Nattermann J. The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C. PLoS One. 2012;7:e38846. [PMID: 22792160 DOI: 10.1371/journal.pone.0038846] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
38 Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012;32:500-509. [PMID: 22098627 DOI: 10.1111/j.1478-3231.2011.02665.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 34] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011;6:e21381. [PMID: 21731723 DOI: 10.1371/journal.pone.0021381] [Cited by in Crossref: 153] [Cited by in F6Publishing: 160] [Article Influence: 13.9] [Reference Citation Analysis]